Friday, August 28, 2015

This week in ePharma: Google Life Sciences joins the Digital Health Race and more!

Pin It Now!
Google search logo
Earlier this week Sergey Brin made an official announcement about the Google's life sciences team moving into a separate Life Sciences venture with its own CEO. These changes are a part of the company's recent reorganization. Life Sciences is aiming big at making progress in health tech sphere. Google Smart Contact lenses is currently the most well-known project under Life Sciences.



Digital health app connected to a mobile device, connected to a computer and a virtual doctor. mHealthComputers are to become more humanized. More and more research companies are working their way into reading human emotions and interpreting them digitally. The goal is to use the data to make health wearables more sensitive to an individual user and therefore increase the effectiveness of the devices. Affectiva is one of the companies conducting such research. With the statement "Leading global expert in emotion analytics and insights" Affective claims to have analyzed 2,756,949 faces to date.


Bayer Healthcare logo
Digital health accelerator program? Sure. Two words: Germany, Bayer. “Grants4Apps Accelerator” program funded by Bayer Healthcare will sponsor five digital health startups who focus their research around such topics as predicting behavior, improve health in the work place, patient empowerment and others. The five health tech companies for Grants4Apps Accelerator 2015 have already been chosen. Within the given 100 days the Bayer Healthcare program guarantees to provide mentorship by Bayer's experts, office space,  and funding of 50,000€.

Another health tech accelerator program is launching, this time locally, in Pittsburgh. A large nonprofit health and wellness company Highmark Health has built VITAL - a program that aims to speed up an approval process for healthcare innovators. The VITAL innovation program promises to simplify the whole procedure from submitting a proposal to its evaluation and funding, and therefore make new technologies available to consumers faster.

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, August 21, 2015

ePharma news: This August - The Ice Bucket Challenge is back | "Viagra" for women is about to hit the market and more

Pin It Now!
The ALS Ice Bucket Challenge is back with the hashtag #EveryAugustUntilACure
Do you remember the Ice Bucket Challenge that took over the world last year? A brilliant campaign that was initiated by ALS Association in hopes to raise money for the Lou Gehrig's disease research, went viral not just in the U.S. but globally as well. By the end of 2014 the ALS Association was able to raise $115 million dollars. This August the Ice Bucket Challenge is back, and the funds collected last year are partially allocated toward the Lou Gehrig's disease research project conducted by Biogen Inc. and the Columbia University Medical Center. Earlier this year Biogen announced a $30-million-dollars funding that the company has committed to (plus, $3.5 million dollars raised by the Ice Bucket Challenge promotion.) The project is said to monitor 1,500 patients with the disease through clinical trial in efforts to find the cure.

Addyi is a "female version" of the Viagra pill produced by Sprout Pharmaceuticals
A "female version" of Viagra has just been approved by the FDA. Addyi is the first of its kind drug aiming at treatment of sexual desire disorders (HSDD) in both genders. HSDD stands for hypoactive sexual desire disorder, and as stated on the FDA official page: "HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. HSDD is acquired when it develops in a patient who previously had no problems with sexual desire." It's noteworthy that the drug manufacturer Sprout Pharmaceuticals has been previously turned down twice, because the benefits of Addyi were said to be outweighed by the side effects and the risks caused by taking the drug. The Addyi drug has been approved with a strong warning against taking it with alcohol and other drugs because of its potentially toxic effect on the organism, and it will only be available through certified medical professionals. 

This week Kite Pharma is on a news but unfortunately not for a break through research but because of one of the patient's death while in a blood cancer clinical trial. The LA Times reported, that during the conference call the Kite Pharma CEO Arie S. Belldegrun stated, "A clinical investigator of the study conducted an in-depth review of the death and concluded that this death was unrelated to our product."
Following the investigation the FDA allowed the Kita Pharma company to continue with clinical trials.

Bionic wearable-technology earbuds Here Active Listening from Dobbler Labs
Image courtesy: http://www.hereplus.me/
Earbuds that will turn down the noise volume around you including the sound of crying babies? - Yes, please! A wearable-technology startup Doppler Labs has invented a wireless earbuds device that aims at increasing and adjusting your hearing depending on your personal comfort level. With the mission "Change the Way We Hear the World" and the price tag of $199, Here Active Listening is targeting audiophiles first. The company has posted a testimony-video by Hans Zimmer, a world-famous Grammy-winning composer, who in his support to the Here Active Listening gadget stated, "The way we find our place in the world is through touch, eyes, and hugely - through ears. You want to be able to select what you hear. It's about having control of your life."


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, August 14, 2015

This week in ePharma: FDA issues a warning to K. Kardashian's promoted morning-sickness drug

Pin It Now!
FDA issues a warning to Diclegis, the morning-sickness drug promoted by Kim Kardashian
In the week of July 24th it was announced that Diclegis has partnered with Kim Kardashian in promotional efforts of the new morning-sickness drug. This week the FDA has issued a warning over K. Kardashian's drug promotion on social media. In particular, it was stated that there was a violation of the federal drug-promotion rules. The reality star has never mentioned any side effects in her testimonial statement favoring the drug on Instagram. On August 7th the FDA has posted a warning letter addressing the drug's and Kardashian's promotional efforts as misleading and indicating that the social post was submitted as a complaint to the OPDP Bad Ad Program, the program that was designed to monitor and supervise the truthfulness of the prescription drug advertising and promotional efforts.

Roche Pharma Research & Early Development has developed a smartphone app to continuously monitor changes in patients with Parkinson’s disease. The hopes are the app will be able to collect data that can significantly improve medicine development program in Parkinson’s disease. Currently the app is in Phase I trial run with the the help of Prothena, a late-stage clinical biotechnology company that focuses on discovery, development and commercialization of programs with aim of potential treatment of diseases.


With the team of researchers from Oxford, Cambridge and London with backgrounds in medicine, behavioral health, bioengineering, design, and software the startup Hinge Health has set a goal to improve the lower back pain for many employees who spend most of the day at their desks, and help their employers reduce absenteeism and health costs. Hinge Health has produced a program that consists of physiotherapy, personalized coaching, weight loss, ability to tracking progress, and peer support opportunity. The program is a package that includes sensor bands, a tablet computer with software, and a number of other accessories. Based in London, the Hinge Health startup is currently aiming at the US market.


FDA has lost a battle for off-label marketing if the claims are truthful.
On August 7th the federal judge of the Federal District Court in Manhattan Paul A. Engelmayer has ruled that off-label marketing can be done legally even if FDA has not approved for as long as the claims are truthful based on the First Amendment (Freedom of Speech.) This precedent sets the history, because in the past many companies have lost this fight in court and ended up paying large settlements.

Here you can read How to Recognize and Report Off-Label Pharmaceutical Marketing.


Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Wednesday, August 12, 2015

Take Your Pharma Sales and Marketing Strategy to the Next Level at PharmaNEXT

Pin It Now!
Innovative, growth-oriented pharma companies are creating integrated commercial strategies to sustain and grow market share. The major shift in the pharma marketplace needs a different operating model where sales and marketing teams must work together and leverage innovation, technology and analytics to develop new go-to-market strategies.

The brand new PharmaNEXT conference will address these changes with boot camps, visionary keynotes, interactive debates, a curated expo hall, and more.

Here’s a look at the innovative sessions formats you will experience at PharmaNEXT:

NEXTTalks: Speakers share progress and report on real life examples of applications, success and failures. Hear from best-in-class practitioners on how to leverage innovation, technology and analytics to create new, effective operating models.

Think Tanks: Attendees split up in open roundtable discussions each based on one industry challenge to solve. Attendees can rotate to join in multiple open discussions on pertinent industry topics.

Bootcamps: Hand-on sessions with tangible takeaways and instant ROI. Take a deep dive into the most relevant topics in the next generation of pharma’s commercial strategy.

Think Tank Recaps: Think Tank leads to share findings with each working group and create actionable solutions for implementation.

Download complete agenda for program details: http://bit.ly/1HGskJY

Join us for next generation strategies and solutions that await you at PharmaNEXT - the latest educational and networking experience focused on elevating your pharma commercial strategy to the next level.

Your future depends on how your respond to this change.

As a valued member of our LinkedIn community you get $100 off the current rate when you register using code XP2040blog:  http://bit.ly/1HGskJY

We hope to see you in Philadelphia this fall!

Cheers,
The Pharma Next 2015 Team
#PharmaNext
@ePharma
epharmasummitblog.iirusa.com


Friday, August 7, 2015

This week in ePharma: The Future is here: FDA o'kays the 3-D printed drug and more!

Pin It Now!
The Future is here! The biotech industry continues to explore the possibilities of 3-D print technology, and one of its latest developments is a 3-D-printed pill.

FDA approves the first 3D-printed drug
FDA gives a go to the first ever 3-D printed drug against epilepsy called SPRITAM. Some of the benefits of a 3-D-printed drug are the ability to manufacture the drugs with high dose of the active element levetiracetam in one dosage and to produce pills identical to one another making it easier for patients to swallow. As NPR stated the drug is expected to hit the market in 2016.




Yelp partners with ProPublica, to provide Yelp's users with with healthcare statistics on hospitals and clinics around in the US. ProPublica is a nonprofit organization based NYC whose mission is "Journalism in the Public Interest." ProPublica does investigative reporting in many fields include healthcare. What Yelp is aiming for is to be able to better navigate its users and help them make more conscious decisions regarding their health. The statistics will include such categories as the number of beds available at a hospital, wait times
and more.

The Next Web in its article "Can tech help overcome addiction?" explores a new trend in mobile app development - mobile health apps focused on creating bonds between people with similar challenges such as sobriety, past drug addiction and others. It's been documented that there's a strong relationship between isolation and addiction, therefore more and more tech start ups shift their attention toward building mobile health apps that provide support from communities of like-minded. One of such mobile health apps is called My Sober Life that aims to support young people in their path to sobriety.

It's been reported that Hospira's Symbiq Infusion System (an IV pump) has a security loop that allows unauthorized users to access the equipment remotely and control the dosage of drugs delivered. And while no security breaches has been revealed, the FDA issued a safety alert urging hospitals to stop using the system as a prevention measure.

 

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, July 31, 2015

This week in ePharma: Self-diagnosis with Wize Mirror and more!

Pin It Now!
The digital revolution is spreading across the pharma and medical industries faster and faster, cutting down the costs of services and the wait time along the way.

ePharma news: Opternative, a digital health company, just launched an app that you can use to take an eye exam at homeAnother bright star on the digital health horizon is Opternative, the company that just launched a $40 online eye exam that everyone can take at home has he/she got a computer, smartphone and Wi-Fi.
As stated by TechCrunch, Opternative today is the only approved online eye exam that if done successfully will issue eye glasses prescription that can be used as online as in your local eye glasses store. The downside is, Opternative cannot diagnose eye diseases, so it is highly recommended to still check with an eye doctor once in a while as a preventative measure.


More and more health devices enter our and become an essential part of lives. Here is another promising gadget that is aiming at diagnosing medical conditions by "scanning" a person's face in the mirror. The idea behind SEMEOTICONS a.k.a. Wize Mirror is to integrate a multi-sensory system into a hardware platform
that looks like a mirror. This hardware will be able to read individual faces, monitor changes in their statuses and provide tailored suggestions about nutrition, physical activity, and more thus creating a platform for self-monitoring.

The smart technology market has expanded dramatically in the last five years coming up with many from business to fitness and health - oriented devices. A South Korean startup Dot has decided to face the fact that there's a large market of visually impaired people, who have the same demands for health wearables but don't have an equal supply. The problem that Dot stated they are trying to solve is out of 285 million visually impaired people, 95% cannot read. The prices for e-braille readers are very appalling and count in thousands of dollars still, therefore most of that 95% stay illiterate. With that in mind, Dot has launched an affordable E-braille smartwatch for visually impaired people. Tech in Asia reports that Dot smartwatch (currently available in Asia only) will go on sale in the United States in December at a retail price of approximately US$300.

A new development in treating obesity: the FDA has just approved a new medical device for a non-surgical obesity treatment - Reshape. Reshape integrates a dual balloon technology, which when inserted orally into a patient's stomach creates a feeling of being full and thus significantly shrinks the portions of food consumed. Combined with special diet and exercises Reshape is said to have natural, promising lasting results. The med device official website also claims, that during the recent studies patients lost more than two times more weight with ReShape than with diet and exercise alone. Plus, they were able to keep most of the lost weight off even after the device has been removed six months later.

Stay tuned for our weekly news round up! 

Subscribe to our Blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Wednesday, July 29, 2015

Tap Into Insiders' Top Secrets to Success at PharmaNEXT, Plus Get $500 Off by July 31st

Pin It Now!
PharmaNEXT is proud to present Jane McGonigal, PhD, New York Times Bestselling Author and Author of SuperBetter - a revolutionary thinker, who will give you the insights on how to apply her award-winning out-of-the-box thinking to pharma.

Fast Company: "Top 100 Creative People in Business"
Oprah Winfrey for O Magazine: "20 Most Inspiring Women in the World"
MIT Technology Review: "Top 35 innovators changing the world through technology"
Business Week: "Top Ten Innovators to Watch"
Harvard Business Review: "Top 20 Breakthrough Ideas"

Whether you are trying to engage the patient or the physician, learn about both ends of the spectrum. These NEXTTalks feature life science professionals who will show you how to reach your evolving target customer and have your message resonate to achieve your desired outcome.

·         Leveraging our Insights for Better Physician Engagement: Jayne Gretz, Vice President, American Medical Association and Leslie Stokes, Senior Vice President for Physician Engagement, American Medical Association
·         Going from Brand Centric to Patient Centric from R&D to Commercialization: Anne C. Beal, MD, MPH
Chief Patient Officer, Center of Excellence for Patient Centricity, Sanofi 

Download complete agenda for details: http://bit.ly/1MtRtOA

Join the participating companies including: Sanofi, Bayer, Astellas, Merck & Co., Inc, Bristol-Meyers Squibb, Mylan, Biogen, Daiichi-Sankyo, AstraZeneca and many more for next generation strategies and solutions that await you at PharmaNEXT - the latest educational and networking experience focused on elevating your pharma commercial strategy to the next level.

Register by July 31st with code 00GKMH7ZD and save $400 off the standard rates. Plus use code XP2040blog and get an additional $100 off – that’s a $500 discount. Register here: http://bit.ly/1MtRtOA

Cheers, 
The Pharma Next 2015 Team
#PharmaNext
@ePharma
epharmasummitblog.iirusa.com




Friday, July 24, 2015

This week in ePharma: Diclegis partners with Kim Kardashian and more

Pin It Now!
The summer is at its full speed, and we are ready to present you with yet another portion of ePharma news of this week!

Would you trust a purple pill against headache? Could a green pill create more trust in you? With this concept in mind researchers decided to find out whether color and shape of pills affected the perception of effectiveness of the drug and people's expectations. As was reported in The Wall Street Journal, the participants of this online study judged pills of three different colors and in seven different shapes. As the result, the white pills were rated as the most affective, and the light green pills caused the participants to become skeptical in terms of its effectiveness in treating headache.




Celebrity buzz: Kim Kardashian is now endorsing Diclegis, also known as a morning sickness drug. Duchesnay USA, the drug maker, and the reality TV star have partnered together to help raise awareness around morning sickness symptom relief that K. Kardashian has allegedly suffered from during both of her pregnancies (until she tried Diclesis.) It's important to point out, that Diclegis is currently the only medication for treatment of nausea and vomiting during pregnancy that's been approved by FDA.

Researchers from Partners Connected Health, the Department of Pulmonology, Massachusetts General Hospital, and pediatric asthma group as a team effort have created a password - protected Facebook group to conduct a 12-month-long asthma study among teens 14-17 years old. Along with the tests researchers sent monthly reminders and important information regarding asthma. The study had an unprecedented engagement results of 79% in comparison to an average 18% of engagement. In the society which is driven by user-generated information, scientists find high engagement results hugely important for the future research and drug development purposes.


Allergan, Botox maker, launched a new internet campaign, #ActuallySheCan, targeting millennial women. According to The Guardian, women make up 62% of their market in the US. The premise of this campaign is to start engaging millennial women and build lifetime loyalty toward the Allergan pharma brands and products. ActuallySheCan is also a website that educates women on birth control and serves as a community space gamifying the user experience from "shemojime" option of creating a unique emoji with the user's face to "gimme the deets" - a program that allows to earn virtual coins to donate to a participating women's charity.

Stay tuned for our weekly news round up! 

Subscribe to our blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Friday, July 17, 2015

This week in ePharma: Feeling ill? Call your doc on Skype or check your symptoms on Figure 1, an Instagram-like app for doctors

Pin It Now!
Social media is drastically changing the way we consume and share information. In 2014 alone the use of social media by adults in the U.S. reached 73% (from 42% in the previous year.) And this number is still growing steadily. These days many fields and industries find it important to provide coverage in social media; it didn't escape healthcare and medical fields.

With many visually focused social media platforms on the market there is now the one that is specifically built for doctors. Figure 1 is a mobile app that enables a thought exchange between doctors across the globe in real time. The idea behind the Figure 1 app is similar to Instagram, where people can upload photos and leave comments, the difference is everyone can download the app but not everyone can create content on it. Figure 1 implements an option of account authentication, and only verified medical professionals can share information to enforce its validity and anonymity. Another, characteristic that Figure 1 features, is the ability to locate a medical professional in your area. The app is said to aim for a bigger goal of distributing knowledge across the international medical community.


Most of us know our family history going a few generations back. But do you know your family's history of deceases? Ancestry.com is set to provide you with that. It just launched AncestryHealth.com in a beta version. The premise of the website it to employ research and expert knowledge to make predictions and suggest preventative measures for users with family history of disorders. For that, Ancestry Health is partnering with 23andMe to use their database information of opted in and consented users.


"Virtual medicine in every house!" could be a slogan for the next news topic. As healthcare rapidly advancing online, it made it possible for doctors' consultations over the Skype. As it was reported in The New York Times, there are more and more doctors willing jump on a quick Skype call - consultation, and more and more patients leaning toward exactly this type of medical assistance instead of paying a visit to a hospital. The pros of virtual medical assistance are the ability to identify and diagnose minor health issues and get a medical assistance on the spot - a drugs prescription can be sent to your local pharmacy right away. The cons are the debatable accuracy of such diagnostics, and lack of insurance coverage still.

Lastly, good news for health-oriented Samsung users: the phone claims to now allow to track body fat with four sensors installed on the device's case. This technology has just been patented and is not yet available. But as stated in Tech Times, if the technology proves to work it will be the first of the kind, since no phone app yet has claimed to be able to track body fat.


Stay tuned for our weekly news round up! 

Subscribe to our blog or follow us on Twitter: @epharma

 

About the author: Ksenia Newton, a Digital Marketing Assistant at IIR USA, Pharma Division, who works on various aspects of the industry including social media, marketing analysis and media. She can be reached at knewton@iirusa.com

Monday, July 13, 2015

Announcing PharmaNEXT: Achieve Commercial Success in a Customer-Centric World

Pin It Now!
PharmaNEXT is where sales and marketing executives looking to reach new customer segments learn from best-in-class practitioners on how to leverage innovation, technology and analytics to create new, effective commercial operating models. 

PharmaNEXT
October 20-22, 2015
Philadelphia, Marriot
Click here to download the agenda: http://bit.ly/1IWcC30

Experience the intensive boot camp style content, cross-industry visionary keynotes, interactive debates, and a Curated Networking and Exhibit Area at PharmaNEXT. Join commercial sales and marketing strategy executives for this one-of-a-kind experience to:

·         Learn the decision-making processes and value definitions of the new customer groups—including ACOs and IDNs.
·         Establish best practices for integrating sales force initiatives and multichannel campaigns to fully engage HCPs with brands.
·         Benchmark your initiatives against cross-industry case studies
·         Construct effective data-driven marketing platforms to strategically engage customers seamlessly across all touchpoints.
·         Network with like-minded peers facing the same challenges as the marketplace commands a different operating model.

Don't miss this opportunity to take away actionable insights that will immediately impact your business.

Register by July 17 and SAVE up to $500 with code XP2040link! Reserve your seat here: http://bit.ly/1IWcC30

Best,
The ePharma/Pharma Next 2015 Team
#PharmaNext
@ePharma